Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case-control study

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 1, 1999, Pages 20-25

  Cauda, Roberto ^a,b   Tacconelli, Evelina ^a   Tumbarello, Mario ^a   Morace, Giulia ^b   De Bernardis, Flavia ^a   Torosantucci, Antonella ^a   Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

AIDS; Candida; HAART Candidosis; HIV; HIV protease inhibitors

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; THRUSH; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0033135992     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199905010-00003     Document Type: Article

References (17)

1. DeEks SG, Smith M, Holodniy I, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-55.
2. Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998;351:228-30.
3. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998;351:256-61.
4. Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med 1996;334:1674-5.
5. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
6. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
7. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of HIV-infected subjects treated with HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321-9.
8. Pakker NG, Roos MTL, van Leeuwen R, et al. Patterns of T cell repopulation, viral load reduction and restoration of T cell function in human immunodeficiency virus infected persons during therapy with different antiretrovirals. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:318-26.
9. Center for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
10. Gomez MJ, Torosantucci A, Arancia S, Maras B, Parisi L, Cassone A. Purification and biochemical characterization of a 65 kilodalton Mannoprotein (MP65), a main target of anti-Candida cell-mediated immune response in humans. Infect Immunol 1996;64:2577-84.
11. Quinti I, Palma C, Guerra EC, et al. Proliferative and cytotoxic responses to mannoproteins of Candida albicans by peripheral blood lymphocytes of HIV-infected subjects. Clin Exp Immunol 1991;85:485-92.
12. Tumbarello M, Caldarola G, Tacconelli E, et al. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. J Antimicrob Chemother 1996;38:691-9.
13. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311;354-58.
14. Kutler JE. Putative virulence factors of Candida albicans. Annu Rev Microbiol 1991;45:187-218.
15. De Bernardis F, Arancia S, Morelli L, et al. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999;179:201-8.
16. Carlesimo M, Pontesilli O, Guerra MC, et al. Long term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) env glycoprotein in HIV-infected persons. J Infect Dis 1997;176;904-12.
17. Cassone A, Adriani D, Tacconelli E, Cauda R, De Bernardis F. HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase [abstract 31211]. Presented at the XII International Conference on AIDS, Geneva, June, 1998.